Merck's sac-TMT improves survival in Phase 3 TroFuse-015 gastroesophageal cancer trial

Merck said Friday, Nov. 20, 2026, that its experimental TROP2-directed antibody-drug conjugate sacituzumab tirumotecan, known as sac-TMT, improved overall survival in a global Phase 3 trial of patients with advanced gastroesophageal adenocarcinoma whose disease had progressed after at least two prior lines of systemic therapy. The Rahway, New Jersey, drugmaker said the TroFuse-015 study met its primary endpoint against chemotherapy chosen by the treating physician, though the drug did not meet the secondary endpoint of progression-free survival. Merck licensed sac-TMT outside Greater China from Kelun-Biotech.
Key developments
- TroFuse-015 (NCT06356311), a randomized, open-label, multicenter Phase 3 trial, enrolled 473 patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma after two or more prior lines of therapy.
- At the final analysis, sac-TMT showed a statistically significant and clinically meaningful improvement in overall survival versus treatment of physician's choice, with results generally consistent across subgroups regardless of TROP2 expression, according to Merck.
- Sac-TMT did not meet the secondary endpoint of progression-free survival by blinded independent central review. Response rate showed a nominal benefit that was not formally tested under the prespecified analysis plan.
- Merck said safety was consistent with earlier sac-TMT studies, with no new signals. No hazard ratios, medians or adverse event figures were released.
- The company called TroFuse-015 the second positive Phase 3 readout in a program of 18 ongoing global Phase 3 trials and said data will go to regulators and an upcoming medical meeting.
Disease and treatment background
Patients in TroFuse-015 had already received at least two lines of systemic treatment, a setting where options narrow sharply. The comparator arm reflects current practice: investigators could choose trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Sac-TMT was dosed at 4 mg/kg on days 1, 15 and 29 of each six-week cycle. Secondary endpoints were progression-free survival, objective response rate and duration of response.
In its release, Merck cited estimates of about 31,500 new gastric cancer cases and 10,700 deaths in the United States in 2026, with adenocarcinomas making up roughly 90% to 95% of gastric malignancies. The company also cited more than 14,300 expected new U.S. cases of esophageal adenocarcinoma, about 42% of which are diagnosed at a distant stage. Early gastric cancer often causes no symptoms, so many patients are diagnosed only after the disease has advanced.
Sac-TMT pairs an antibody against TROP2, a protein expressed on many solid tumors, with a belotecan-derived topoisomerase I inhibitor payload through a bifunctional linker. Kelun-Biotech, a subsidiary of Kelun Pharmaceutical, developed the drug. Merck holds exclusive rights to develop, manufacture and commercialize it in all territories outside Mainland China, Hong Kong, Macau and Taiwan.
Industry implications
The result gives the TROP2 class its first overall survival win in a global Phase 3 study in gastroesophageal cancer, according to Merck. Overall survival is the endpoint regulators and payers weigh most heavily in late-line solid tumors, so a positive primary readout matters even without a progression-free survival benefit. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, said the drug is the "first TROP2 ADC to improve OS" against physician's choice in this disease and pointed to a tremendous unmet need for therapies that extend survival.
The mixed secondary results will shape how the data are received. A survival gain without a matching progression-free survival benefit can raise questions about the size of the effect and how it was achieved, and Merck has not yet released the numbers. The magnitude of the hazard ratio, median survival and the toxicity profile, including rates of anemia and neutropenia seen in earlier sac-TMT studies, will determine how physicians weigh the drug against established third-line regimens.
TroFuse-015 follows TroFuse-005 in endometrial cancer. In results presented at ESMO 2026 on Oct. 26, sac-TMT cut the risk of death by 32% versus chemotherapy in previously treated endometrial cancer, and the FDA accepted a biologics license application with a target action date of June 15, 2027, according to Merck.
Competitive and supply chain implications
TROP2-directed ADCs have become one of oncology's most contested drug classes. Other products targeting TROP2 have been approved in breast cancer, and several developers are testing the class across lung, bladder and gastrointestinal tumors. Merck describes the TroFuse program, which spans more than nine disease areas and more than 15,000 patients, as the broadest of any TROP2-directed ADC. Fourteen of its 18 Phase 3 trials target first-in-class opportunities.
The deal structure means two companies stand to gain. Kelun-Biotech keeps Greater China, where BioSpace reported the drug is already approved in four indications, while Merck carries global development and manufacturing elsewhere. Antibody-drug conjugates require specialized capacity for antibody production, highly potent payload synthesis and conjugation, so a widening set of indications increases the importance of Merck's manufacturing planning and its contract partners.
Regional implications
Gastric cancer is far more common in East Asia than in the United States, so global trial results with consistent subgroup effects are important for filings in Japan, South Korea and Europe as well as in the U.S. Merck has not said which agencies will receive the TroFuse-015 data first or when filings will occur.
In the United States, the comparator regimens are standard late-line options, so a survival benefit, if confirmed in full data, would position sac-TMT as a new choice after two lines of therapy. In China, Kelun-Biotech controls the asset, and the two companies' regulatory paths will move on separate tracks.
Credence Research analysis
The readout strengthens Merck's case that sac-TMT can become a multi-tumor oncology franchise rather than a single-indication drug. Two positive Phase 3 survival results in different cancers within six months give the company momentum as it prepares for its first U.S. decision in endometrial cancer next June. The open question is effect size. Until Merck publishes the hazard ratio and medians, investors and clinicians cannot judge whether the gain is large enough to change late-line practice.
The missed progression-free survival endpoint also signals that results in gastrointestinal tumors may differ from those in gynecologic cancers. The finding that benefit held regardless of TROP2 expression could simplify use, since patients would not need a biomarker test, but regulators will want to see the subgroup data. For the wider ADC sector, the outcome supports continued investment in TROP2 programs, while showing that survival, not tumor shrinkage alone, will decide the class's value in hard-to-treat cancers.
What comes next
- Full TroFuse-015 data, including hazard ratio, median overall survival and safety, at an upcoming medical meeting not yet named by Merck.
- Submission of the data to regulatory authorities, with timing and agencies to be disclosed.
- FDA action on the sac-TMT application in previously treated endometrial cancer, with a target date of June 15, 2027.
- Further readouts from the remaining Phase 3 trials in the TroFuse program, including first-line studies.
- Kelun-Biotech regulatory updates for the drug in Greater China.
Sources
- Merck: TroFuse-015 trial met primary endpoint of overall survival (Nov. 20, 2026)
- Merck: TroFuse-005 endometrial cancer results (Oct. 26, 2026)
- ClinicalTrials.gov: NCT06356311
- BioSpace: Merck-Kelun ADC scores survival win in Phase 3 gastroesophageal cancer trial
Image: Merck Research Laboratories in South San Francisco, California, by Coolcaesar via Wikimedia Commons, CC BY-SA 4.0. Cropped and edited by Credence Research.
About the Author

Senior News Editor at Credence Research Inc